Detection of Lung Cancer by Sensor Array Analyses of Exhaled Breath

Electronic noses are successfully used in commercial applications, including detection and analysis of volatile organic compounds in the food industry. We hypothesized that the electronic nose could identify and discriminate between lung diseases, especially bronchogenic carcinoma. In a discovery an...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	American journal of respiratory and critical care medicine Ročník 171; číslo 11; s. 1286 - 1291
Hlavní autoři:	Machado, Roberto F, Laskowski, Daniel, Deffenderfer, Olivia, Burch, Timothy, Zheng, Shuo, Mazzone, Peter J, Mekhail, Tarek, Jennings, Constance, Stoller, James K, Pyle, Jacqueline, Duncan, Jennifer, Dweik, Raed A, Erzurum, Serpil C
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	New York, NY Am Thoracic Soc 01.06.2005 American Lung Association American Thoracic Society
Témata:	Adult Aged Aged, 80 and over Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Breath Tests - methods Chromatography, Gas Clinical death. Palliative care. Organ gift and preservation Cross-Sectional Studies F. Lung Cancer and Oncologic Disorders False Negative Reactions Female Humans Intensive care medicine Lung Neoplasms - diagnosis Male Mass Spectrometry Medical sciences Middle Aged Pneumology Principal Component Analysis Reproducibility of Results Sensitivity and Specificity Tumors of the respiratory system and mediastinum Volatile compound Lung disease Intensive care bronchogenic cancer Respiratory disease volatile organic compounds Lung cancer Electronics electronic nose Malignant tumor Medical screening Breath test Nose Resuscitation Organic compounds breath tests
ISSN:	1073-449X, 1535-4970
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Electronic noses are successfully used in commercial applications, including detection and analysis of volatile organic compounds in the food industry. We hypothesized that the electronic nose could identify and discriminate between lung diseases, especially bronchogenic carcinoma. In a discovery and training phase, exhaled breath of 14 individuals with bronchogenic carcinoma and 45 healthy control subjects or control subjects without cancer was analyzed. Principal components and canonic discriminant analysis of the sensor data was used to determine whether exhaled gases could discriminate between cancer and noncancer. Discrimination between classes was performed using Mahalanobis distance. Support vector machine analysis was used to create and apply a cancer prediction model prospectively in a separate group of 76 individuals, 14 with and 62 without cancer. Principal components and canonic discriminant analysis demonstrated discrimination between samples from patients with lung cancer and those from other groups. In the validation study, the electronic nose had 71.4% sensitivity and 91.9% specificity for detecting lung cancer; positive and negative predictive values were 66.6 and 93.4%, respectively. In this population with a lung cancer prevalence of 18%, positive and negative predictive values were 66.6 and 94.5%, respectively. The exhaled breath of patients with lung cancer has distinct characteristics that can be identified with an electronic nose. The results provide feasibility to the concept of using the electronic nose for managing and detecting lung cancer.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Undefined-3 This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Correspondence and requests for reprints should be addressed to Serpil C. Erzurum, M.D., Cleveland Clinic Foundation, 9500 Euclid Avenue/NB40, Cleveland, OH 44195. E-mail: erzurus@ccf.org Conflict of Interest Statement: R.F.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; D.L. is the owner of Physiologic Measurement Systems LLC, which builds gas-sampling systems; O.D. is employed by Smiths Detection, which sponsored the study through the loan of the electronic nose detection device; T.B. is employed by Smiths Detection, which sponsored the study through loan of the electronic nose detection device; S.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; P.J.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; T.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; C.J. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; J.K.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; J.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; J.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; R.A.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; S.C.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Supported by the National Institutes of Health grant NIH HL04265 and Smiths Detection, Inc., through donation of the electronic nose instrument and partial financial support for research supplies.
ISSN:	1073-449X 1535-4970
DOI:	10.1164/rccm.200409-1184OC